108 related articles for article (PubMed ID: 24172042)
1. AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer--culprits for resistance to EGFR inhibitors?
Heideman MR; Hynes NE
Breast Cancer Res; 2013; 15(5):315. PubMed ID: 24172042
[TBL] [Abstract][Full Text] [Related]
2. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
4. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
7. Involvement of pp60c-src with two major signaling pathways in human breast cancer.
Luttrell DK; Lee A; Lansing TJ; Crosby RM; Jung KD; Willard D; Luther M; Rodriguez M; Berman J; Gilmer TM
Proc Natl Acad Sci U S A; 1994 Jan; 91(1):83-7. PubMed ID: 7506422
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.
Golubovskaya V; Beviglia L; Xu LH; Earp HS; Craven R; Cance W
J Biol Chem; 2002 Oct; 277(41):38978-87. PubMed ID: 12167618
[TBL] [Abstract][Full Text] [Related]
9. Role of epidermal growth factor receptor in breast cancer.
Masuda H; Zhang D; Bartholomeusz C; Doihara H; Hortobagyi GN; Ueno NT
Breast Cancer Res Treat; 2012 Nov; 136(2):331-45. PubMed ID: 23073759
[TBL] [Abstract][Full Text] [Related]
10. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
Itoh T; Hatano R; Horimoto Y; Yamada T; Song D; Otsuka H; Shirakawa Y; Mastuoka S; Iwao N; Aune TM; Dang NH; Kaneko Y; Okumura K; Morimoto C; Ohnuma K
Cell Death Dis; 2021 May; 12(6):520. PubMed ID: 34021125
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.
Peace BE; Hill KJ; Degen SJ; Waltz SE
Exp Cell Res; 2003 Oct; 289(2):317-25. PubMed ID: 14499632
[TBL] [Abstract][Full Text] [Related]
12. AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells.
Zajac O; Leclere R; Nicolas A; Meseure D; Marchiò C; Vincent-Salomon A; Roman-Roman S; Schoumacher M; Dubois T
Cells; 2020 Jan; 9(1):. PubMed ID: 31963783
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
14. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
Inoue S; Patil R; Portilla-Arias J; Ding H; Konda B; Espinoza A; Mongayt D; Markman JL; Elramsisy A; Phillips HW; Black KL; Holler E; Ljubimova JY
PLoS One; 2012; 7(2):e31070. PubMed ID: 22355336
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.
Secq V; Villeret J; Fina F; Carmassi M; Carcopino X; Garcia S; Metellus I; Boubli L; Iovanna J; Charpin C
Br J Cancer; 2014 Feb; 110(4):1045-52. PubMed ID: 24423920
[TBL] [Abstract][Full Text] [Related]
16. An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway.
Santoro M; Wong WT; Aroca P; Santos E; Matoskova B; Grieco M; Fusco A; di Fiore PP
Mol Cell Biol; 1994 Jan; 14(1):663-75. PubMed ID: 8264635
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the role of the Shc and Grb2 proteins in signal transduction by the v-ErbB protein.
Meyer S; LaBudda K; McGlade J; Hayman MJ
Mol Cell Biol; 1994 May; 14(5):3253-62. PubMed ID: 7909355
[TBL] [Abstract][Full Text] [Related]
18. The high transforming potency of erbB-2 and ret is associated with phosphorylation of paxillin and a 23 kDa protein.
Romano A; Wong WT; Santoro M; Wirth PJ; Thorgeirsson SS; Di Fiore PP
Oncogene; 1994 Oct; 9(10):2923-33. PubMed ID: 7916147
[TBL] [Abstract][Full Text] [Related]
19. Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Irwin ME; Bohin N; Boerner JL
Cancer Biol Ther; 2011 Oct; 12(8):718-26. PubMed ID: 21775822
[TBL] [Abstract][Full Text] [Related]
20. ELP-dependent expression of
Cruz-Gordillo P; Honeywell ME; Harper NW; Leete T; Lee MJ
Sci Signal; 2020 Nov; 13(658):. PubMed ID: 33203722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
